HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model 

Aug 23, 2024 - 02:34 PM
340B pic

Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto. Starting Oct. 15, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and submit data to J&J. Upon verification of the drug’s 340B status, DSHs would receive a rebate for the discounted 340B price.

Last week, the AHA contacted the Health Resources and Services Administration for more information as soon as it was made aware that J&J was considering these actions. HRSA notified the AHA today that it has informed J&J that its rebate model is inconsistent with the 340B statute and that this model has not been approved by the Secretary of the Department of Health and Human Services. HRSA further informed the AHA that it will take appropriate action as warranted.
 

Related News Articles

Headline
AHA comments to MedPAC on 2024-2025 cycle 
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…
Headline
AHA comments on 340B ACCESS Act, shares new 340B infographic 
The AHA July 26 submitted a letter expressing concerns in response to the recently introduced 340B Affording Care for Communities and Ensuring a Strong Safety-…
Headline
AHA, others file briefs in Maryland, West Virginia to prevent injunctions against 340B pricing for contract pharmacy arrangements
The AHA, 340B Health, Maryland Hospital Association and Mid-Atlantic Association of Community Health Centers July 9 filed an amicus brief in a federal district…
Headline
AHA submits comments on CMS draft guidance for Medicare drug price negotiation program
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…
Headline
Mississippi judge denies drug maker’s and PhRMA’s request for preliminary injunction in 340B case
A Mississippi judge July 1 denied Novartis Pharmaceuticals’ and PhRMA’s request for a preliminary injunction against enforcement of state law protecting 340B…
Headline
AHA, others file amicus brief in Maryland to prevent injunction against 340B pricing for contract pharmacy arrangements 
The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal…